FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV) (Gileadl)
A Phase 3, Randomized Trial ofBulevirtide in Chronic Hepatitis D(NEJM)
Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD) (NLM: ClinicalTrials.gov)
Andes Hantavirus Outbreak on a Cruise Ship, 2026 (NEJM)
Quick takes: Another hantavirus case, polio in 3 countries, NIAID head steps down (CIDRAP)
Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial (CID)
Dolutegravir Appears to Lower Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) Proviral Load: The Emerging Rational Approach to Treatment of HTLV-1–Associated Myelopathy (CID)
Urinary Tract Infection (UTI)-free and Recurrent UTI (rUTI)-Free Survivals Following Bladder Electrofulguration in Women With a History of Antibiotic-Refractory rUTI (OFID)
Impact of introducing RTS,S/AS01E malaria vaccine on mortality in young children in Ghana, Kenya, and Malawi: an observational evaluation of a cluster-randomised implementation programme (The LANCET)
Ivermectin-Benzimidazole Prescribing Following Celebrity Endorsement (JAMA Network OPEN)
Infectious Diseases Fellowship Curriculum: IDSA Training Program Directors Community of Practice (TPDCOP), Curricular and Educational REsources Workgroup (CREW) (CID)
Podden och tillhörande omslagsbild på den här sidan tillhör
Vincent Racaniello. Innehållet i podden är skapat av Vincent Racaniello och inte av,
eller tillsammans med, Poddtoppen.